Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Leukemia·2026
Same author

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Bone marrow transplantation·2026
Same author

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Blood·2026
Same author

AI for the assessment and discovery of morphological-molecular biomarker relationships in hematologic malignancies.

Blood reviews·2026
Same author

Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group.

Bone marrow transplantation·2026
Same author

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Nature medicine·2026

Related Experiment Video

Updated: Sep 3, 2025

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.4K

High-Throughput CRISPR Screening in Hematological Neoplasms.

Raquel Ancos-Pintado1,2, Irene Bragado-García2, María Luz Morales1

  • 1Department of Translational Hematology, Instituto de Investigación Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, CIBERONC, ES 28041 Madrid, Spain.

Cancers
|July 27, 2022
PubMed
Summary

CRISPR screening is revolutionizing hematology research by identifying genes linked to drug resistance and new therapeutic targets in blood cancers. This review details CRISPR applications for discovering biomarkers and understanding immune evasion in hematological neoplasms.

Keywords:
CRISPRalgorithmshematological neoplasmslibrariesresistancesvulnerabilities

More Related Videos

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

307
HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
10:10

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

8.4K

Related Experiment Videos

Last Updated: Sep 3, 2025

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.4K
Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

307
HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
10:10

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

8.4K

Area of Science:

  • Genomics
  • Biotechnology
  • Hematology

Background:

  • CRISPR technology is a powerful tool revolutionizing biological research and biotechnology.
  • CRISPR-based genome-targeting tools are increasingly applied to study hematological neoplasms.
  • A gap exists in comprehensive reviews focusing on CRISPR applications specifically within hematology.

Purpose of the Study:

  • To review CRISPR-based high-throughput screening approaches in hematology.
  • To highlight the identification of novel genes modulating drug resistance and efficacy.
  • To discuss the discovery of new therapeutic targets, biomarkers, and immune evasion mechanisms in hematological neoplasms.

Main Methods:

  • Summarizing main CRISPR-based high-throughput screening approaches used in hematology.
  • Explaining CRISPR libraries and analysis algorithms relevant to hematology.
  • Compiling relevant databases for CRISPR screen analysis in hematological research.

Main Results:

  • Identification of novel modulator genes for drug resistance and efficacy, aiding in relapse prediction.
  • Discovery of new therapeutic targets and synthetic lethal interactions.
  • Uncovering novel biomarkers for malignant transformations and immune evasion mechanisms.

Conclusions:

  • CRISPR screening is crucial for advancing hematology research, particularly in understanding drug resistance and identifying therapeutic strategies.
  • Further validation of gene candidates and data harmonization from CRISPR screens are essential for future progress.
  • This technology holds significant promise for developing novel diagnostics and treatments for hematological neoplasms.